Current Challenges in the Management of Tuberculosis
Vivek Srivastava1★, Ananya Verma1★ Corresponding author
- 1Department of Pharmacology, Amity institute of Pharmacy, Amity University, Lucknow, Uttar Pradesh, INDIA.
CORRESPONDENCE
Vivek Srivastava
Department of Pharmacology, Amity institute of Pharmacy, Amity University, Lucknow, Uttar Pradesh, INDIA.
Received: 05-02-2024; Revised: 30-03-2024; Accepted: 01-04-2024.
Volume 16, Issue 2 · pp. 145–154 · PUBLISHED · DOI: 10.5530/jyp.2024.16.21
ABSTRACT
The global fight against Tuberculosis (TB) persists; grappling with approximately 10.6 million new cases in 2021, as documented in the 2022 WHO Global TB Report.1 Of concern is the escalating incidence of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB), which saw an estimated 450,000 new cases in the same year. Today's major problem in the treatment of MycobacteriumTB is drug resistance brought on by anti-TB therapy. The degree of resistance led to variations and other effects that eventually ended in death and health risks. The advent of certain drug-resistant strains of TB that are resistant to several treatments, prolonged drugs and all drugs is going to bring a major and catastrophic comeback to the disease. Current advancements in TB treatment help to reduce anti-tubercular medication resistance. Due to Mycobacterium tuberculosis'sextraordinary flexibility, drug resistance in tuberculosis is a complicated phenomenon. Via genetic mutations, efflux pumps and other processes, these bacteria may become resistant to anti-TB medications. Hence, against drug-resistant bacteria, conventional TB treatment regimens-which usually include a mix of antibiotics-may stop working. The worldwide account will lose about 200,000 due to medication resistance fatalities in a single year. The development of vaccines against tuberculosis is a promising topic, but progress has been hampered by a lack of funding, organization and understanding of immunological responses. A Tubercular Vaccine Accelerator Council will combine resources and expertise to tackle these issues and accelerate development. Accomplish the WHO's goal of TB eradication by 2030.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Srivastava, V., & Verma, A. (). Current Challenges in the Management of Tuberculosis. Journal of Young Pharmacists, 16(2), 145–154. https://doi.org/10.5530/jyp.2024.16.21